The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2010 Financial Results

Wednesday, May 12, 2010

Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2010 Financial Results09:00 EDT Wednesday, May 12, 2010HOUSTON, May 12 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced that the company will report financial results for the fourth quarter and fiscal year ended April 30, 2010 on Wednesday, June 2, 2010 at 5:00 PM EDT. �The company will conduct a conference call to discuss those results on Thursday, June 3, 2010 at 9:00 AM EDT.Fourth Quarter and Fiscal Year 2010 Results Conference Call InstructionsTo listen to the conference call live by telephone dial 877-313-8035 (if dialing from within the U.S.) or 706-679-4838 (if dialing from outside the U.S.). �The conference ID is 71879824. �Presentation slides will be available on-line at no later than 8:00 AM EDT on Thursday, June 3, 2010. �A replay of the conference call will be available approximately two hours after the completion of the conference call by dialing 800-642-1687 (if dialing from within the U.S.) or 706-645-9291 (if dialing from outside the U.S.). �The replay conference ID access code is 71879824. �The replay will be available for one week on the above number and subsequently on the company's website for a period of six months.About Cyberonics, Inc. and VNS Therapy�Cyberonics, Inc. (NASDAQ:CYBX) is a medical technology company with core expertise in neuromodulation. �The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. �The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. �Cyberonics markets the VNS Therapy System in approximately 60 countries worldwide, and to date more than 55,000 patients have been implanted with the device.Additional information on Cyberonics and VNS Therapy is available at INFORMATION:Greg Browne, CFOCyberonics, Inc.100 Cyberonics Blvd.Houston, TX 77058Main: �(281) 228-7262Fax: �(281) 218-9332ir@cyberonics.comSOURCE Cyberonics, Inc.For further information: Greg Browne, CFO of Cyberonics, Inc., +1-281-228-7262, fax, +1-281-218-9332,